# DXC Technology Co: Form 10-Q for the period ended Dec 31, 2020

- Company: [DXC Technology Co](/companies/dxc.md) (CIK 1688568)
- Form: 10-Q
- Filed: 2021-02-05
- Accepted by EDGAR: Feb 4, 2021, 19:24 ET
- Period: 2020-12-31
- Accession: 0001688568-21-000008
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1688568/000168856821000008/dxc-20201231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1688568/000168856821000008/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-10-01 to 2020-12-31 | $4.29bn | us-gaap:Revenues |
| Revenue | 9 months, 2020-04-01 to 2020-12-31 | $13.34bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months, 2020-10-01 to 2020-12-31 | $517.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-04-01 to 2020-12-31 | $1.59bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-10-01 to 2020-12-31 | $300.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-04-01 to 2020-12-31 | $773.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-10-01 to 2020-12-31 | $82.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-04-01 to 2020-12-31 | $284.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-10-01 to 2020-12-31 | $875.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-04-01 to 2020-12-31 | $789.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-10-01 to 2020-12-31 | $1.10bn | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-04-01 to 2020-12-31 | $649.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-10-01 to 2020-12-31 | $4.29 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-04-01 to 2020-12-31 | $2.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-10-01 to 2020-12-31 | $4.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-04-01 to 2020-12-31 | $2.55 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-10-01 to 2020-12-31 | 255,750,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-04-01 to 2020-12-31 | 255,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-04-01 to 2020-12-31 | $404.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-04-01 to 2020-12-31 | $215.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2020-04-01 to 2020-12-31 | $53.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2020-12-31 | $3.92bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-12-31 | $9.11bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-12-31 | $23.63bn | us-gaap:Assets |
| Current liabilities | at 2020-12-31 | $8.27bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-12-31 | $17.64bn | us-gaap:Liabilities |
| Long-term debt | at 2020-12-31 | $5.44bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-12-31 | $252.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2020-12-31 | $112.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2020-12-31 | $5.66bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 51,130 characters.

### Introduction

The purpose of the MD&A is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the third quarter and first nine months of fiscal 2021 and our financial condition as of December 31, 2020. The MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and accompanying notes.

The MD&A is organized into the following sections:

- Background
- Results of Operations
- Liquidity and Capital Resources
- Off-Balance Sheet Arrangements
- Contractual Obligations
- Critical Accounting Policies and Estimates

The following discussion includes a comparison of our results of operations and liquidity and capital resources for the third quarters and first nine months of fiscal 2021 and fiscal 2020.

### Background

DXC Technology helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences.

We generate revenue by offering a wide range of information technology services and solutions primarily in North America, Europe, Asia and Australia. We operate through two segments: Global Business Services ("GBS") and Global Infrastructure Services ("GIS"). We market and sell our services directly to clients through our direct sales force operating out of sales offices around the world. Our clients include commercial businesses of many sizes and in many industries and public sector enterprises.

### Results of Operations

The following table sets forth certain financial data for the third quarters and first nine months of fiscal 2021 and fiscal 2020:

*(In millions, except per-share amounts)*

|  | Three Months Ended December 31, 2020 | December 31, 2019 | Nine Months Ended December 31, 2020 | December 31, 2019 |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $4,288 | $5,021 | $13,344 | $14,762 |
| Income (loss) before income taxes | 1,978 | 127 | 1,447 | (1,666) |
| Income tax expense | 875 | 37 | 789 | 191 |
| Net income (loss) | $1,103 | $90 | $658 | $(1,857) |
| Diluted earnings (loss) per common share: | $4.29 | $0.32 | $2.54 | $(7.20) |

### Fiscal 2021 Highlights

Financial highlights for the third quarter and first nine months of fiscal 2021 include the following:

- Revenues for the third quarter and first nine months of fiscal 2021 were $4.3 billion and $13.3 billion, respectively, a decrease of 14.6% and 9.6%, respectively, as compared to the third quarter and first nine months of fiscal 2020. These decreases were primarily due to the disposition of the HHS business at the beginning of the third quarter of fiscal 2021, project terminations, and changes in run volume. The decrease in revenue for the first nine months of fiscal 2021 was partially offset by contributions from our Luxoft acquisition which was executed during the first quarter of fiscal 2020. Refer to the section below captioned "Revenues."
- Net income and diluted earnings per share for the third quarter of fiscal 2021 were $1,103 million and $4.29, respectively. Net income increased by $1,013 million during the third quarter of fiscal 2021 as compared to the same period of the prior fiscal year. The increase was primarily due to gain on disposition of businesses and cost optimization realized in the current year, partially offset by a reduction in revenue previously mentioned and an increase in tax expense from prior year. Refer to the section below captioned "Cost and Expenses." Net income included the cumulative impact of certain items of $882 million during the quarter, reflecting restructuring costs, transaction, separation and integration-related costs, amortization of acquired intangible assets, and gain on disposition of businesses. This compares with net income and diluted earnings per share of $90 million and $0.32, respectively, for the third quarter of fiscal 2020.
- Net income and diluted earnings per share for the first nine months of fiscal 2021 were $658 million and $2.54, respectively. Net income increased by $2,515 million during the first nine months of fiscal 2021 as compared to the same period of the prior fiscal year. The increase was primarily due to goodwill impairment recognized in the prior year and gain on disposition of businesses and cost optimization realized in the current year partially offset by gain on arbitration in the prior year and a reduction in revenue in the current year previously mentioned. Refer to the section below captioned "Cost and Expenses." Net income included the cumulative impact of certain items of $217 million during the period, reflecting restructuring costs, transaction, separation and integration-related costs, amortization of acquired intangible assets, gain on disposition of businesses, pension and other post-retirement benefit ("OPEB") actuarial and settlement losses, and tax adjustment. This compares with net loss and diluted loss per share of $1,857 million and $7.20, respectively, for the first nine months of fiscal 2020.
- Our cash and cash equivalents were $3.9 billion as of December 31, 2020.
- We generated $404 million of cash from operations during the first nine months of fiscal 2021, as compared to $2,062 million during the first nine months of fiscal 2020.

### Revenues

*(in millions)*

|  | Three Months Ended December 31, 2020 | December 31, 2019 | Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| GBS | $1,921 | $2,359 | $(438) | (18.6)% |
| GIS | 2,367 | 2,662 | (295) | (11.1)% |
| Total Revenues | $4,288 | $5,021 | $(733) | (14.6)% |

*(in millions)*

|  | Nine Months Ended December 31, 2020 | December 31, 2019 | Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| GBS | $6,337 | $6,803 | $(466) | (6.8)% |
| GIS | 7,007 | 7,959 | (952) | (12.0)% |
| Total Revenues | $13,344 | $14,762 | $(1,418) | (9.6)% |

The decrease in revenues for the third quarter and first nine months of fiscal 2021, compared with the same periods in fiscal 2020, reflects the disposition of the HHS business at the beginning of the third quarter of fiscal 2021, project terminations, and changes in run volume. The decrease in revenue for the first nine months of fiscal 2021 was partially offset by contributions from our Luxoft acquisition which was executed during the first quarter of fiscal 2020. Revenues for the third quarter and first nine months of fiscal 2021 included favorable foreign currency exchange rate impacts of 2.3% and 0.6%, respectively. These impacts were primarily driven by the weakening of the U.S. dollar against the Euro, Australian Dollar, and British Pound during the third quarter and first nine months of fiscal 2021.

During the third quarters and first nine months of fiscal 2021 and fiscal 2020, the distribution of our revenues across geographies was as follows:

For the discussion of risks associated with our foreign operations, see Part 1, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.

As a global company, over 65% of our revenues for the first nine months of fiscal 2021 were earned internationally. As a result, the comparison of revenues denominated in currencies other than the U.S. dollar, from period to period, is impacted by fluctuations in foreign currency exchange rates. Constant currency revenues are a non-GAAP measure calculated by translating current period activity into U.S. dollars using the comparable prior period’s currency conversion rates. This information is consistent with how management views our revenues and evaluates our operating performance and trends. The table below summarizes our constant currency revenues:

*(in millions)*

|  | Three Months Ended Constant Currency December 31, 2020 | December 31, 2019 | Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| GBS | $1,868 | $2,359 | $(491) | (20.8)% |
| GIS | 2,302 | 2,662 | (360) | (13.5)% |
| Total | $4,170 | $5,021 | $(851) | (16.9)% |

*(in millions)*

|  | Nine Months Ended Constant Currency December 31, 2020 | December 31, 2019 | Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| GBS | $6,287 | $6,803 | $(516) | (7.6)% |
| GIS | 6,962 | 7,959 | (997) | (12.5)% |
| Total | $13,249 | $14,762 | $(1,513) | (10.2)% |

54

#### Global Business Services

Our GBS revenues were $1,921 million in the third quarter and $6,337 million in the first nine months of fiscal 2021, a decrease of 18.6% and 6.8%, respectively, compared to the corresponding periods in fiscal 2020. GBS revenue in constant currency decreased 20.8% and 7.6% in the third quarter and first nine months of fiscal 2021, respectively, as compared to the corresponding periods in fiscal 2020. The decrease in GBS revenues for the third quarter and first nine months of fiscal 2021 were primarily due to the disposition of the HHS business at the beginning of the third quarter of fiscal 2021, project terminations, and change in run volumes. The decrease in revenue for the first nine months of fiscal 2021 was partially offset by contributions from our Luxoft acquisition which was executed during the first quarter of fiscal 2020.

For the third quarter and first nine months of fiscal 2021, GBS contract awards were $2.7 billion and $8.6 billion, respectively, as compared to $2.5 billion and $6.8 billion in the corresponding periods of fiscal 2020.

#### Global Infrastructure Services

Our GIS revenues were $2,367 million in the third quarter and $7,007 million in the first nine months of fiscal 2021, a decrease of 11.1% and 12.0%, respectively, compared to the corresponding periods in fiscal 2020. GIS revenue in constant currency decreased 13.5% and 12.5% in the third quarter and first nine months of fiscal 2021, respectively, as compared to the corresponding periods in fiscal 2020. The decrease in GIS revenues for the third quarter and first nine months of fiscal 2021 reflects project terminations, change in run volumes, and price-downs.

For the third quarter and first nine months of fiscal 2021, GIS contract awards were $2.2 billion and $6.5 billion, respectively, as compared to $2.8 billion and $6.5 billion in the corresponding periods of fiscal 2020.

### Costs and Expenses

Our total costs and expenses are shown in the tables below:

*(in millions)*

|  | Three Months Ended Amount December 31, 2020 | December 31, 2019 | Percentage of Revenues December 31, 2020 | December 31, 2019 | Percentage Point Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Costs of services (excludes depreciation and amortization and restructuring costs) | $3,333 | $3,827 | 77.8% | 76.2% | 1.6 |
| Selling, general, and administrative (excludes depreciation and amortization and restructuring costs) | 517 | 518 | 12.1 | 10.3 | 1.8 |
| Depreciation and amortization | 475 | 479 | 11.1 | 9.5 | 1.6 |
| Goodwill impairment losses | — | 53 | — | 1.1 | (1.1) |
| Restructuring costs | 104 | 74 | 2.4 | 1.5 | 0.9 |
| Interest expense | 82 | 93 | 1.9 | 1.9 | — |
| Interest income | (28) | (33) | (0.7) | (0.7) | — |
| Gain on disposition of businesses | (2,046) | — | (47.7) | — | (47.7) |
| Other income, net | (127) | (117) | (3.0) | (2.3) | (0.7) |
| Total costs and expenses | $2,310 | $4,894 | 53.9% | 97.5% | (43.6) |

*(in millions)*

|  | Nine Months Ended Amount December 31, 2020 | December 31, 2019 | Percentage of Revenues December 31, 2020 | December 31, 2019 | Percentage Point Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Costs of services (excludes depreciation and amortization and restructuring costs) | $10,525 | $11,128 | 78.9% | 75.3% | 3.6 |
| Selling, general, and administrative (excludes depreciation and amortization and restructuring costs) | 1,595 | 1,514 | 12.0 | 10.3 | 1.7 |
| Depreciation and amortization | 1,492 | 1,416 | 11.2 | 9.6 | 1.6 |
| Goodwill impairment losses | — | 2,940 | — | 19.9 | (19.9) |
| Restructuring costs | 441 | 248 | 3.3 | 1.7 | 1.6 |
| Interest expense | 284 | 288 | 2.1 | 2.0 | 0.1 |
| Interest income | (76) | (130) | (0.6) | (0.9) | 0.3 |
| Gain on disposition of businesses | (2,046) | — | (15.3) | — | (15.3) |
| Gain on arbitration award | — | (632) | — | (4.3) | 4.3 |
| Other income, net | (318) | (344) | (2.4) | (2.3) | (0.1) |
| Total costs and expenses | $11,897 | $16,428 | 89.2% | 111.3% | (22.1) |

The 43.6 and 22.1 point decrease in total costs and expenses as a percentage of revenue for the third quarter and first nine months of fiscal 2021 primarily reflects the gain on disposition of businesses in the current year and our goodwill impairment losses incurred during the third quarter and first nine months of fiscal 2020 that didn’t occur in fiscal 2021.

### Costs of Services

Costs of services, excluding depreciation and amortization and restructuring costs ("COS"), was $3.3 billion and $10.5 billion for the third quarter and first nine months of fiscal 2021, respectively. COS decreased $494 million and $603 million during the third quarter and first nine months of fiscal 2021, respectively, as compared to the same periods of the prior fiscal year. These decreases were primarily due to cost optimization savings realized during fiscal 2021. COS as a percentage of revenue increased 1.6 and 3.6 points, respectively, as compared to the same periods of the prior fiscal year. These point increases were driven by a reduction in revenue during the same periods of the current fiscal year.

### Selling, General, and Administrative

Selling, general, and administrative expense, excluding depreciation and amortization and restructuring costs ("SG&A"), was $517 million for the third quarter of fiscal 2021, consistent with the same period of the prior fiscal year. SG&A was $1,595 million for the first nine months of fiscal 2021, an increase of $81 million compared to the same period of the prior fiscal year. The increase during the first nine months of fiscal 2021 was driven by higher transaction, separation and integration-related costs.

Transaction, separation and integration-related costs of $96 million and $307 million were included in SG&A for the third quarter and first nine months of fiscal 2021, respectively, as compared to $68 million and $226 million for the comparable period of the prior fiscal year.

### Depreciation and Amortization

Depreciation expense was $185 million and $563 million for the third quarter and first nine months of fiscal 2021, respectively. Depreciation expense increased $49 million and $91 million during the third quarter and first nine months of fiscal 2021, respectively, as compared to the same periods of the prior fiscal year. The net increase in depreciation expense for the third quarter and first nine months of fiscal 2021 was due to an increase in assets placed into service.

Amortization expense was $290 million and $929 million for the third quarter and first nine months of fiscal 2021, respectively. Amortization expense decreased $53 million and $15 million during the third quarter and first nine months of fiscal 2021, respectively, as compared to the same periods of the prior fiscal year. These decreases were primarily due to customer related intangibles related to the disposition of the HHS business at the beginning of the third quarter of fiscal 2021. See Note 4 - "Divestitures" for additional information.

### Goodwill Impairment Losses

DXC recognized goodwill impairment charges totaling $53 million and $2,940 million for the third quarter and first nine months of fiscal 2020, respectively. The impairment charge was primarily as a result of a decline in market capitalization during the second quarter of fiscal 2020. See Note 11 - "Goodwill" for additional information.

### Restructuring Costs

During fiscal 2021, management approved global cost savings initiatives designed to better align our workforce and facility structures. During the third quarter and first nine months of fiscal 2021, restructuring costs, net of reversals, were $104 million and $441 million, respectively, as compared to $74 million and $248 million during the same periods of the prior fiscal year. In addition, during the third quarter of fiscal 2021 workforce reductions includes a $14 million adjustment to restructuring expense related to the prior year.

For an analysis of changes in our restructuring liabilities by restructuring plan, see Note 14 - "Restructuring Costs" to the financial statements.

### Interest Expense and Interest Income

Interest expense was $82 million and $284 million for third quarter and first nine months of fiscal 2021, respectively. Interest expense decreased $11 million and $4 million during the third quarter and first nine months of fiscal 2021, respectively, as compared to the same periods of the prior fiscal year. These decreases were primarily driven by lower interest rates on finance leases and a reduction in interest charges within our multicurrency cash pools. The decrease in interest expense for the first nine months of fiscal 2021 was partially offset by increased amounts drawn on our revolving credit facility.

Interest income was $28 million and $76 million for third quarter and first nine months of fiscal 2021, respectively. Interest income decreased $5 million and $54 million during the third quarter and first nine months of fiscal 2021, respectively, as compared to the same periods of the prior fiscal year. The decrease during the third quarter of fiscal 2021 was primarily driven by lower income from our multicurrency cash pools and money market accounts. The decrease during the first nine months of fiscal 2021 was primarily driven by interest income in the second quarter of fiscal year 2020 related to arbitration discussed below under the caption “Gain on Arbitration Award."

### Gain on Dispositions

During the third quarter of fiscal 2021, DXC sold its U.S. State and Local Health and Human Services business for a total enterprise value of $5.0 billion and resulted in an estimated pre-tax gain on sale of $2,041 million, net of closing costs. An insignificant business was also sold during the quarter that resulted in a gain of $5 million.

### Gain on Arbitration Award

During the second quarter of fiscal 2020, DXC received final arbitration award proceeds of $666 million related to the HPE Enterprise Services merger completed in fiscal 2018. The arbitration award included $632 million in damages that were recorded as a gain. The remaining $34 million of the award related to pre-award interest. Dispute details are subject to confidentiality obligations.

### Other Income, Net

Other income, net comprises non-service cost components of net periodic pension income, movement in foreign currency exchange rates on our foreign currency denominated assets and liabilities and the related economic hedges, equity earnings of unconsolidated affiliates and other miscellaneous gains and losses.

Other income was $127 million and $318 million for the third quarter and first nine months of fiscal 2021, respectively, as compared to $117 million and $344 million during the same periods of the prior fiscal year.

The $10 million increase in other income, net for the third quarter of fiscal 2021, as compared to the same period of the prior fiscal year, was primarily due to a year-over-year increase in other gains related to sales of non-operating assets partially offset by foreign exchange hedging and revaluations.

The $26 million decrease in other income, net for the first nine months of fiscal 2021, as compared to the same period of the prior fiscal year, was primarily due to foreign exchange hedging and revaluations, partially offset by a year-over-year increase in gains related to sales of non-operating assets.

### Taxes

Our effective tax rate ("ETR") was 44.2% and 29.1% for the three months ended December 31, 2020 and December 31, 2019, respectively, and 54.5% and (11.5)% for the nine months ended December 31, 2020 and December 31, 2019, respectively. For the three and nine months ended December 31, 2020, the primary drivers of the ETR were the gain on sale of HHS Business, global mix of income and foreign tax credits. For the three months ended December 31, 2019, the primary drivers of the ETR were the impact of previously unrecognized tax effects on the tax deductible goodwill impaired during the fiscal 2020 second quarter, the global mix of income, an increase in prior year U.S. federal research and development income tax credits, and an increase in unrecognized tax benefits primarily related to audit activity. For the nine months ended December 31, 2019, the primary drivers of the ETR were the impact of the non-deductible goodwill impairment charge, the non-taxable gain on the arbitration award, the global mix of income, an increase in unrecognized tax benefits primarily related to audit activity, and an increase in prior year U.S. federal research and development income tax credits, net.

### Earnings (Loss) Per Share

Diluted earnings per share for the third quarter and first nine months of fiscal 2021 was $4.29 and $2.54, respectively. Diluted earnings per share increased $3.97 and $9.74 during the third quarter and first nine months of fiscal 2021, respectively, as compared to the same periods of the prior fiscal year. This increase was due to an increase of $1,013 million and $2,515 million in net income for the third quarter and first nine months of fiscal 2021, respectively, over the same periods in the prior fiscal year.

Diluted earnings per share for the third quarter of fiscal 2021 includes $0.36 per share of restructuring costs, $0.31 per share of transaction, separation and integration-related costs, $0.34 per share of amortization of acquired intangible assets, and $(4.47) per share of gain on disposition of businesses.

Diluted earnings per share for the first nine months of fiscal 2021 includes $1.43 per share of restructuring costs, $0.93 per share of transaction, separation and integration-related costs, $1.25 per share of amortization of acquired intangible assets, $(4.48) per share of gain on disposition of businesses, $0.01 per share of pension and OPEB actuarial and settlement losses, and $0.01 of tax adjustment.

### Non-GAAP Financial Measures

We present non-GAAP financial measures of performance which are derived from the statements of operations of DXC. These non-GAAP financial measures include earnings before interest and taxes ("EBIT"), adjusted EBIT, non-GAAP income before income taxes, non-GAAP net income and non-GAAP EPS, constant currency revenues, net debt and net debt-to-total capitalization.

We present these non-GAAP financial measures to provide investors with meaningful supplemental financial information, in addition to the financial information presented on a GAAP basis. Non-GAAP financial measures exclude certain items from GAAP results which DXC management believes are not indicative of core operating performance. DXC management believes these non-GAAP measures allow investors to better understand the financial performance of DXC exclusive of the impacts of corporate-wide strategic decisions. DXC management believes that adjusting for these items provides investors with additional measures to evaluate the financial performance of our core business operations on a comparable basis from period to period. DXC management believes the non-GAAP measures provided are also considered important measures by financial analysts covering DXC, as equity research analysts continue to publish estimates and research notes based on our non-GAAP commentary, including our guidance around diluted non-GAAP EPS targets.

Non-GAAP financial measures exclude certain items from GAAP results which DXC management believes are not indicative of operating performance such as the amortization of acquired intangible assets, transaction, separation and integration-related costs, and gains and losses on dispositions of businesses.

Incremental amortization of intangible assets acquired through business combinations may result in a significant difference in period over period amortization expense on a GAAP basis. We exclude amortization of certain acquired intangibles assets as these non-cash amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. Although DXC management excludes amortization of acquired intangible assets primarily customer related intangible assets, from its non-GAAP expenses, we believe that it is important for investors to understand that such intangible assets were recorded as part of purchase accounting and support revenue generation. Any future transactions may result in a change to the acquired intangible asset balances and associated amortization expense.

There are limitations to the use of the non-GAAP financial measures presented in this report. One of the limitations is that they do not reflect complete financial results. We compensate for this limitation by providing a reconciliation between our non-GAAP financial measures and the respective most directly comparable financial measure calculated and presented in accordance with GAAP. Additionally, other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes between companies.

Selected references are made on a “constant currency basis” so that certain financial results can be viewed without the impact of fluctuations in foreign currency rates, thereby providing comparisons of operating performance from period to period. Financial results on a “constant currency basis” are non-GAAP measures calculated by translating current period activity into U.S. dollars using the comparable prior period’s currency conversion rates. This approach is used for all results where the functional currency is not the U.S. dollar. Please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Fiscal 2021 Highlights.”

Certain non-GAAP financial measures and the respective most directly comparable financial measures calculated and presented in accordance with GAAP include:

*(in millions)*

|  | Three Months Ended December 31, 2020 | December 31, 2019 | Change |
| --- | ---: | ---: | ---: |
| Income before income taxes | $1,978 | $127 | $1,851 |
| Non-GAAP income before income taxes | $246 | $468 | $(222) |
| Net Income | $1,103 | $90 | $1,013 |
| Adjusted EBIT | $300 | $528 | $(228) |

*(in millions)*

|  | Nine Months Ended December 31, 2020 | December 31, 2019 | Change |
| --- | ---: | ---: | ---: |
| Income (loss) before income taxes | $1,447 | $(1,666) | $3,113 |
| Non-GAAP income before income taxes | $565 | $1,551 | $(986) |
| Net income (loss) | $658 | $(1,857) | $2,515 |
| Adjusted EBIT | $773 | $1,709 | $(936) |

#### Reconciliation of Non-GAAP Financial Measures

Our non-GAAP adjustments include:

- Restructuring costs - reflects costs, net of reversals, related to workforce optimization and real estate charges.
- Transaction, separation and integration-related (“TSI”) costs - reflects costs to execute on strategic alternatives, costs related to integration, planning, financing and advisory fees associated with the HPES Merger and other acquisitions and costs related to the separation of USPS and other divestitures.(1)
- Amortization of acquired intangible assets - reflects amortization of intangible assets acquired through business combinations.
- Gain on disposition of businesses - Reflects gains and losses related to sales of businesses.
- Pension and OPEB actuarial and settlement gains and losses - reflects pension and OPEB actuarial and settlement gains and losses.
- Goodwill impairment losses - reflects impairment losses on goodwill.
- Gain on arbitration award - reflects a gain related to the HPES merger arbitration award.
- Tax adjustment - for fiscal 2021 periods, reflects the impact of tax entries related to prior restructuring charges and an adjustment to the tax expense relating to USPS, and for fiscal 2020 periods, reflects the impact of tax entries related to prior restructuring charges. Income tax expense of non-GAAP adjustments is computed by applying the jurisdictional tax rate to the pre-tax adjustments on a jurisdictional basis.

*(1) TSI costs for all periods presented include fees and other internal and external expenses associated with legal, accounting, consulting, due diligence, investment banking advisory, and other services, as well as financing fees, retention incentives, and resolution of transaction related claims in connection with, or resulting from, exploring or executing potential acquisitions, dispositions and strategic alternatives, whether or not announced or consummated.*

*TSI-Related Costs for Q3 FY21 include $77 million of costs to execute the strategic alternatives (including $52M for the sale of HHS which closed in October 2020 and $23M for the sale of the healthcare software business which is expected to close later this year); $7 million in expenses related to integration projects resulting from the CSC – HPE ES merger (including costs associated with continuing efforts to separate certain IT systems) and $12 million of costs incurred in connection with activities related to other acquisitions and divestitures.*

A reconciliation of reported results to non-GAAP results is as follows:

*(in millions, except per-share amounts)*

|  | Three Months Ended December 31, 2020 As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Gain on Disposition of Businesses | Non-GAAP Results |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Costs of services (excludes depreciation and amortization and restructuring costs) | $3,333 | $— | $— | $— | $— | $3,333 |
| Selling, general, and administrative (excludes depreciation and amortization and restructuring costs) | 517 | — | (96) | — | — | 421 |
| Income (loss) before income taxes | 1,978 | 104 | 96 | 114 | (2,046) | 246 |
| Income tax expense (benefit) | 875 | 11 | 16 | 26 | (903) | 25 |
| Net income (loss) | 1,103 | 93 | 80 | 88 | (1,143) | 221 |
| Less: net income attributable to non-controlling interest, net of tax | 5 | — | — | — | — | 5 |
| Net income (loss) attributable to DXC common stockholders | $1,098 | $93 | $80 | $88 | $(1,143) | $216 |
| Effective Tax Rate | 44.2% |  |  |  |  | 10.2% |
| Basic EPS | $4.32 | $0.37 | $0.31 | $0.35 | $(4.49) | $0.85 |
| Diluted EPS | $4.29 | $0.36 | $0.31 | $0.34 | $(4.47) | $0.84 |
| Weighted average common shares outstanding for: |  |  |  |  |  |  |
| Basic EPS | 254.32 | 254.32 | 254.32 | 254.32 | 254.32 | 254.32 |
| Diluted EPS | 255.75 | 255.75 | 255.75 | 255.75 | 255.75 | 255.75 |

*(in millions, except per-share amounts)*

|  | Nine Months Ended December 31, 2020 As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Gain on Disposition of Businesses | Pension and OPEB Actuarial and Settlement Losses | Tax Adjustment | Non-GAAP Results |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Costs of services (excludes depreciation and amortization and restructuring costs) | $10,525 | $— | $— | $— | $— | $— | $— | $10,525 |
| Selling, general, and administrative (excludes depreciation and amortization and restructuring costs) | 1,595 | — | (314) | — | — | — | — | 1,281 |
| Income (loss) before income taxes | 1,447 | 441 | 307 | 414 | (2,046) | 2 | — | 565 |
| Income tax expense (benefit) | 789 | 75 | 70 | 95 | (903) | — | (2) | 124 |
| Net income (loss) | 658 | 366 | 237 | 319 | (1,143) | 2 | 2 | 441 |
| Less: net income attributable to non-controlling interest, net of tax | 9 | — | — | — | — | — | — | 9 |
| Net income (loss) attributable to DXC common stockholders | $649 | $366 | $237 | $319 | $(1,143) | $2 | $2 | $432 |
| Effective Tax Rate | 54.5% |  |  |  |  |  |  | 21.9% |
| Basic EPS | $2.55 | $1.44 | $0.93 | $1.26 | $(4.50) | $0.01 | $0.01 | $1.70 |
| Diluted EPS | $2.54 | $1.43 | $0.93 | $1.25 | $(4.48) | $0.01 | $0.01 | $1.69 |
| Weighted average common shares outstanding for: |  |  |  |  |  |  |  |  |
| Basic EPS | 254.03 | 254.03 | 254.03 | 254.03 | 254.03 | 254.03 | 254.03 | 254.03 |
| Diluted EPS | 255.20 | 255.20 | 255.20 | 255.20 | 255.20 | 255.20 | 255.20 | 255.20 |

62

*(in millions, except per-share amounts)*

|  | Three Months Ended December 31, 2019 As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Goodwill Impairment Losses | Tax Adjustment | Non-GAAP Results |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Costs of services (excludes depreciation and amortization and restructuring costs) | $3,827 | $— | $— | $— | $— | $— | $3,827 |
| Selling, general, and administrative (excludes depreciation and amortization and restructuring costs) | 518 | — | (68) | — | — | — | $450 |
| Income before income taxes | 127 | 74 | 68 | 146 | 53 | — | 468 |
| Income tax expense (benefit) | 37 | 10 | 16 | 34 | 53 | (10) | 140 |
| Net income | 90 | 64 | 52 | 112 | — | 10 | 328 |
| Less: net income attributable to non-controlling interest, net of tax | 8 | — | — | — | — | — | 8 |
| Net income attributable to DXC common stockholders | $82 | $64 | $52 | $112 | $— | $10 | $320 |
| Effective Tax Rate | 29.1% |  |  |  |  |  | 29.9% |
| Basic EPS | $0.32 | $0.25 | $0.20 | $0.44 | $— | $0.04 | $1.25 |
| Diluted EPS | $0.32 | $0.25 | $0.20 | $0.44 | $— | $0.04 | $1.25 |
| Weighted average common shares outstanding for: |  |  |  |  |  |  |  |
| Basic EPS | 255.09 | 255.09 | 255.09 | 255.09 | 255.09 | 255.09 | 255.09 |
| Diluted EPS | 256.05 | 256.05 | 256.05 | 256.05 | 256.05 | 256.05 | 256.05 |

*(in millions, except per-share amounts)*

|  | Nine Months Ended December 31, 2019 As Reported | Restructuring Costs | Transaction, Separation and Integration-Related Costs | Amortization of Acquired Intangible Assets | Goodwill Impairment Losses | Gain on Arbitration Award | Tax Adjustment | Non-GAAP Results |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Costs of services (excludes depreciation and amortization and restructuring costs) | $11,128 | $— | $— | $— | $— | $— | $— | $11,128 |
| Selling, general, and administrative (excludes depreciation and amortization and restructuring costs) | 1,514 | — | (226) | — | — | — | — | $1,288 |
| (Loss) income before income taxes | (1,666) | 248 | 226 | 435 | 2,940 | (632) | — | 1,551 |
| Income tax expense (benefit) | 191 | 42 | 43 | 99 | 53 | — | (39) | 389 |
| Net (loss) income | (1,857) | 206 | 183 | 336 | 2,887 | (632) | 39 | 1,162 |
| Less: net income attributable to non-controlling interest, net of tax | 17 | — | — | — | — | — | — | 17 |
| Net (loss) income attributable to DXC common stockholders | $(1,874) | $206 | $183 | $336 | $2,887 | $(632) | $39 | $1,145 |
| Effective Tax Rate | (11.5)% |  |  |  |  |  |  | 25.1% |
| Basic EPS | $(7.20) | $0.79 | $0.70 | $1.29 | $11.09 | $(2.43) | $0.15 | $4.40 |
| Diluted EPS | $(7.20) | $0.79 | $0.70 | $1.28 | $11.03 | $(2.42) | $0.15 | $4.38 |
| Weighted average common shares outstanding for: |  |  |  |  |  |  |  |  |
| Basic EPS | 260.24 | 260.24 | 260.24 | 260.24 | 260.24 | 260.24 | 260.24 | 260.24 |
| Diluted EPS | 260.24 | 261.69 | 261.69 | 261.69 | 261.69 | 261.69 | 261.69 | 261.69 |

63

A reconciliation of net income to EBIT and adjusted EBIT is as follows:

*(in millions)*

|  | Three Months Ended December 31, 2020 | December 31, 2019 | Nine Months Ended December 31, 2020 | December 31, 2019 |
| --- | ---: | ---: | ---: | ---: |
| Net income (loss) | $1,103 | $90 | $658 | $(1,857) |
| Income tax expense | 875 | 37 | 789 | 191 |
| Interest income | (28) | (33) | (76) | (130) |
| Interest expense | 82 | 93 | 284 | 288 |
| EBIT | 2,032 | 187 | 1,655 | (1,508) |
| Restructuring costs | 104 | 74 | 441 | 248 |
| Transaction, separation and integration-related costs | 96 | 68 | 307 | 226 |
| Amortization of acquired intangible assets | 114 | 146 | 414 | 435 |
| Gain on disposition of businesses | (2,046) | — | (2,046) | — |
| Pension and OPEB actuarial and settlement losses | — | — | 2 | — |
| Goodwill impairment losses | — | 53 | — | 2,940 |
| Gain on arbitration award | — | — | — | (632) |
| Adjusted EBIT | $300 | $528 | $773 | $1,709 |

64

### Liquidity and Capital Resources

### Cash and Cash Equivalents and Cash Flows

As of December 31, 2020, our cash and cash equivalents ("cash") was $3.9 billion, of which $1.1 billion was held outside of the U.S. We maintain various multi-currency, multi-entity, cross-border, physical and notional cash and pool arrangements with various counterparties to manage liquidity efficiently that enables participating subsidiaries to draw on the Company’s pooled resources to meet liquidity needs.

A significant portion of the cash held by our foreign subsidiaries is not expected to be impacted by U.S. federal income tax upon repatriation. However, a portion of this cash may still be subject to foreign and U.S. state income tax consequences upon future remittance. Therefore, if additional funds held outside the U.S. are needed for our operations in the U.S., we plan to repatriate these funds not designated as indefinitely reinvested.

We have $0.5 billion in cash held by foreign subsidiaries used for local operations that is subject to country-specific limitations which may restrict or result in increased costs in the repatriation of these funds. In addition, other practical considerations may limit our use of consolidated cash. This includes cash of $0.5 billion held in a German financial services subsidiary subject to regulatory requirements, and $0.2 billion held by majority owned consolidated subsidiaries where third-parties hold minority interests.

The following table summarizes our cash flow activity:

*(in millions)*

|  | Nine Months Ended December 31, 2020 | December 31, 2019 | Change |
| --- | ---: | ---: | ---: |
| Net cash provided by operating activities | $404 | $2,062 | $(1,658) |
| Net cash provided by (used in) investing activities | 4,500 | (2,122) | 6,622 |
| Net cash used in financing activities | (4,671) | (305) | (4,366) |
| Effect of exchange rate changes on cash and cash equivalents | 20 | 26 | (6) |
| Cash classified within current assets held for sale | (13) | — | (13) |
| Net increase (decrease) in cash and cash equivalents | $240 | $(339) | $579 |
| Cash and cash equivalents at beginning of year | 3,679 | 2,899 |  |
| Cash and cash equivalents at end of period | $3,919 | $2,560 |  |

#### Operating cash flow

Net cash provided by operating activities during the first nine months of fiscal 2021 was $404 million as compared to $2,062 million during the comparable period of the prior fiscal year. The decrease of $1,658 million was due to a decrease in net income, net of adjustments of $2,687 million, including $272 million of repurchased receivables previously sold under the Milano Receivables Facility and $12 million of prepaid maintenance related to the sale of the HHS business. The decrease was partially offset by a decrease in working capital cash outflows of $1,029 million. Net loss, net of adjustments includes cash received on arbitration award of $668 million in the prior fiscal year.

#### Investing cash flow

Net cash provided by (used in) investing activities during the first nine months of fiscal 2021 was $4,500 million as compared to $(2,122) million during the comparable period of the prior fiscal year. The decrease in cash used of $6,622 million was primarily due to cash received from business dispositions of $4,942 million in fiscal 2021, a decrease in cash paid for acquisitions of $1,987 million, and the absence of short-term investing of $75 million in fiscal 2020. This was partially offset by a decrease in cash collections related to deferred purchase price receivable of $354 million and a $48 million increase in payments for software licenses related to the sale of the HHS business.

#### Financing cash flow

Net cash used in financing activities during the first nine months of fiscal 2021 was $4,671 million as compared to $305 million during the comparable period of the prior fiscal year. The $4,366 million increase in cash used was primarily due to an increase in repayments, net of borrowings, of $3,102 million on term loans and other long-term debt, $1,500 million on lines of credit, and $590 million on commercial paper. In total, we used $3.5 billion of the net proceeds from the sale of the HHS business to repay debt during the quarter. These increases were partially offset by the absence of common stock repurchases and advance payment for accelerated share repurchase of $736 million in fiscal 2020, and a decrease in dividend payments of $108 million.

### Capital Resources

See Note 21 - "Commitments and Contingencies" for a discussion of the general purpose of guarantees and commitments. The anticipated sources of funds to fulfill such commitments are listed below and under the subheading "Liquidity."

The following table summarizes our total debt:

*(in millions)*

|  | As of December 31, 2020 | March 31, 2020 |
| --- | ---: | ---: |
| Short-term debt and current maturities of long-term debt | $795 | $1,276 |
| Long-term debt, net of current maturities | 5,444 | 8,672 |
| Total debt | $6,239 | $9,948 |

The $3.7 billion decrease in total debt during the first nine months of fiscal 2021 was primarily attributed to the prepayment of $1.5 billion of Revolver Credit Facility outstanding at fiscal year-end March 31, 2020, €402 million of Euro commercial paper, and the following term loan facilities: €750 million of Euro Term Loan due fiscal 2022 and 2023, A$800 million of AUD Term Loan due fiscal 2022, £450 million of GBP Term Loan due fiscal 2022, $481 million of USD Term Loan due fiscal 2025, and €350 million of Euro Term Loan due fiscal 2024. These were partially offset by the issuance of new senior notes with an aggregate principal of $1.0 billion, consisting of (i) $500 million of 4.00% Senior Notes due fiscal 2024 and (ii) $500 million of 4.13% Senior Notes due fiscal 2026.

During the first quarter of fiscal 2021, we applied for and were confirmed eligible to participate in the Bank of England’s (“BOE”) COVID Corporate Funding Facility, a BOE program that provides term liquidity funding to investment grade corporate issuers with significant operations in the UK, in order to stabilize and facilitate continued access to sterling commercial paper markets. At our option, we can borrow up to a maximum of €1.0 billion or its equivalent in Euro, British Pound and U.S. dollar. On June 15, 2020, DXC Capital Funding DAC (previously named DXC Capital Funding Limited), an indirect subsidiary of the Company, issued £600 million in commercial paper maturing May 2021 under its existing €1.0 billion commercial paper program via direct sale to the BOE.

In October 2020, we sold the HHS business and used approximately $3.5 billion of the proceeds to prepay $1,250 million of Revolver Credit Facility, £600 million of GBP commercial paper (approximately $772 million), €350 million of Euro Term Loan due fiscal 2024 (approximately $410 million), $381 million of USD Term loan due fiscal 2025, A$500 million of AUD Term Loan due fiscal 2022 (approximately $358 million), and €250 million of Euro Term Loan due fiscal 2022 and 2023 (approximately $292 million).

During fiscal 2021, we borrowed the remaining $2.5 billion under the $4.0 billion credit facility agreement and repaid the full $4.0 billion on the same. The purpose of the borrowing was to mitigate our reliance on volatile short-term commercial paper markets and to strengthen our cash and liquidity position given the uncertainties related to COVID-19 pandemic and its potential impact on our clients and our business. The credit facility repayment resulted from the availability of other liquidity resources. The entire $4.0 billion credit facility is available for redraw at our request.

We were in compliance with all financial covenants associated with our borrowings as of December 31, 2020 and December 31, 2019.

The debt maturity chart below summarizes the future maturities of long-term debt principal for fiscal years subsequent to December 31, 2020, and excludes maturities of borrowings for assets acquired under long-term financing and finance lease liabilities. See Note 12 - "Debt" for more information.

The following table summarizes our capitalization ratios:

*(in millions)*

|  | As of December 31, 2020 | March 31, 2020 |
| --- | ---: | ---: |
| Total debt | $6,239 | $9,948 |
| Cash and cash equivalents(1) | 3,919 | 3,679 |
| Net debt(2) | $2,320 | $6,269 |
| Total debt | $6,239 | $9,948 |
| Equity | 5,995 | 5,129 |
| Total capitalization | $12,234 | $15,077 |
| Debt-to-total capitalization | 51.0% | 66.0% |
| Net debt-to-total capitalization(2) | 19.0% | 41.6% |

*(1) Includes previously described cash held outside of the U.S., at a German financial services subsidiary, and at majority owned consolidated subsidiaries.*

*(2) Net debt and Net debt-to-total capitalization are non-GAAP measures used by management to assess our ability to service our debts using only our cash and cash equivalents. We present these non-GAAP measures to assist investors in analyzing our capital structure in a more comprehensive way compared to gross debt based ratios alone.*

Our credit ratings are as follows:

| Rating Agency Fitch Moody's | Long Term Ratings BBB Baa2 | Short Term Ratings F-2 P-2 | Outlook Stable Negative |
| --- | --- | ---: | --- |
| S&P | BBB- | - | Stable |

See Note 21 - "Commitments and Contingencies" for a discussion of the general purpose of guarantees and commitments. The anticipated sources of funds to fulfill such commitments are listed below at "Liquidity."

### Liquidity

We expect our existing cash and cash equivalents, together with cash generated from operations, will be sufficient to meet our normal operating requirements for the next 12 months. We expect to continue using cash generated by operations as a primary source of liquidity; however, should we require funds greater than that generated from our operations to fund discretionary investment activities, such as business acquisitions, we have the ability to raise capital through debt financing and the issuance of capital market debt instruments. In addition, we currently utilize and will further utilize our cross currency cash pool for liquidity needs. However, there is no guarantee that we will be able to obtain debt financing, if required, on terms and conditions acceptable to us, if at all, in the future.

Our exposure to operational liquidity risk is primarily from long-term contracts which require significant investment of cash during the initial phases of contracts. The recovery of these investments is over the life of contracts and is dependent upon our performance as well as customer acceptance.

The following table summarizes our total liquidity:

*(in millions)*

|  | As of December 31, 2020 |
| --- | ---: |
| Cash and cash equivalents | $3,919 |
| Available borrowings under our revolving credit facility | 4,000 |
| Total liquidity | $7,919 |

### Share Repurchases

During the first quarter of fiscal 2018, our Board of Directors authorized the repurchase of up to $2.0 billion of our common stock and during the third quarter of fiscal 2019, our Board of Directors approved an incremental $2.0 billion share repurchase. This program became effective on April 3, 2017 with no end date established. There were no share repurchases during the third quarter ended December 31, 2020.

### Dividends

To maintain our financial flexibility we continue to suspend payment of quarterly dividends.

### Off-Balance Sheet Arrangements

In the normal course of business, we are party to arrangements that include guarantees, the receivables securitization facility and certain other financial instruments with off-balance sheet risk, such as letters of credit and surety bonds. We also use performance letters of credit to support various risk management insurance policies. No liabilities related to these arrangements are reflected in our condensed consolidated balance sheets. There have been no material changes to our off-balance-sheet arrangements reported under Part II, Item 7 of our Annual Report on Form 10-K other than as disclosed below and in Note 6 - "Receivables" and Note 21 - "Commitments and Contingencies" to the financial statements in this Quarterly Report on Form 10-Q.

### Contractual Obligations

With the exception of the new senior notes with an aggregate principal amount of $1.0 billion, consisting of (i) $500 million of 4.00% Senior Notes due fiscal 2024; and (ii) $500 million of 4.13% Senior Notes due fiscal 2026; prepayment of $1.5 billion of Revolver Credit Facility, €402 million of Euro commercial paper, and term loan facilities consisting of (i) €750 million of Euro Term Loan due fiscal 2023, (ii) A$800 million of AUD Term Loan due fiscal 2022, (iii) £450 million of GBP Term Loan due fiscal 2022, (iv) $481 million of USD Term Loan due fiscal 2025, and (v) €350 million of Euro Term Loan due fiscal 2024 as discussed above under the subheading "Capital Resources," there have been no material changes, outside the ordinary course of business, to our contractual obligations since March 31, 2020. For further information see "Contractual Obligations" in Item 7 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020.

### Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities. These estimates may change in the future if underlying assumptions or factors change. Accordingly, actual results could differ materially from our estimates under different assumptions, judgments or conditions. We consider the following policies to be critical because of their complexity and the high degree of judgment involved in implementing them: revenue recognition, income taxes, business combinations, defined benefit plans and valuation of assets. We have discussed the selection of our critical accounting policies and the effect of estimates with the audit committee of our board of directors. During the three months ended December 31, 2020, there were no changes to our accounting estimates from those described in our fiscal 2020 Annual Report on Form 10-K except as mentioned in Note 1 - "Summary of Significant Accounting Policies."

## Market risk

As filed, 317 characters.

For quantitative and qualitative disclosures about market risk affecting DXC, see "Quantitative and Qualitative Disclosures About Market Risk" in Item 7A of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020. Our exposure to market risk has not changed materially since March 31, 2020.

## Controls and procedures

As filed, 5,272 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2020 because of the material weakness in our internal control over financial reporting described below.

#### Control Activities

As previously disclosed during the third quarter of fiscal 2020, Management concluded there was a material weakness in internal controls over financial reporting related to the design and implementation of effective control activities based on the criteria established in the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control – Integrated Framework (2013). These control deficiencies constituted a material weakness in the aggregate related to reassessing policies and procedures, to determine their continued relevance, as impacted by complex transactions and processes.

As a result, we have concluded that there is a reasonable possibility that a material misstatement to our Condensed Consolidated Financial Statements would not be prevented or detected on a timely basis and therefore we concluded that the aggregation of these deficiencies represents a material weakness in our internal control over financial reporting as of December 31, 2020.

Notwithstanding the identified material weakness, management believes that the Condensed Consolidated Financial Statements and related financial information included in this 10-Q fairly present, in all material respects, our balance sheets, statements of operations, comprehensive (loss) income and cash flows as of and for the periods presented.

#### Remediation Plan

Management has taken and will continue to take significant and comprehensive actions to remediate the material weakness. Management has completed a detailed root cause analysis, which was designed to identify areas of focus where enhancements can be made to the internal control environment. While we have made progress in remediation of certain of the identified deficiencies that led to the material weakness, our focus is on creating a sustainable controls environment as we build out our remediation program.

The following activities are designed as part of this remediation plan:

- Align the Sarbanes-Oxley Act (“SOX") risk assessment and testing function under the newly appointed Chief Risk Officer with the traditional SOX controls responsibilities including material weakness remediation activities aligned directly under our new Chief Financial Officer.
- Established an enhanced material weakness remediation progress reporting process to the Audit Committee in Q4 FY20.
- Assessed and augmented personnel to ensure appropriate resources are in place to strengthen the overall control environment. We appointed a new Chief Financial Officer in Q3 FY21 with previous experience as a Chief Accounting Officer and in the remediation of material weaknesses. In addition, we hired new leadership in the Finance and Risk organizations with relevant controls and remediation experience in FY21.
- Evaluate and assess key enterprise controls and relevant policies focusing on thresholds, ownership, and accountability.
- Enhance our financial cadence and discipline including reviewing the underlying performance of the business and related balance sheet accounts.
- Standardize processes and rationalize controls across the enterprise to focus on risk.

These additional remediation efforts, identified to comprehensively address our analysis of the root causes, have begun and are expected to be completed in the subsequent quarters. Given the additional remediation activities we do not expect to be completed by the end of the fiscal year. After management’s remediation efforts are complete, subsequent testing is required to conclude that a material weakness no longer exists.

Our goal is to have enhanced control policies, procedures, processes in place as promptly as practicable, however we are not in a position to complete our remediation plan and concluded that our internal control over financial reporting is not designed or operating effectively as of the quarter ended December 31, 2020.

#### Changes in Internal Control over Financial Reporting

In addition to the remediation efforts described above, we adopted ASC 326 effective April 1, 2020, as described in Note 2 - “Recent Accounting Pronouncements” to the financial statements during the first quarter of fiscal 2021. We began using a new model and redesigned certain processes and controls relating to our reserves and expected losses.

There were no changes in our internal control over financial reporting during the three months ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,350 characters.

*Our operations and financial results are subject to various risks and uncertainties, which may materially and adversely affect our business, financial condition, and results of operations, and the actual outcome of matters as to which forward-looking statements are made in this Quarterly Report on Form 10-Q. In such case, the trading price for DXC common stock could decline, and you could lose all or part of your investment. Past performance may not be a reliable indicator of future financial performance and historical trends should not be used to anticipate results or trends in future periods. There have been no material changes in the three months ended December 31, 2020 to the risk factors described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020 and in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 and September 30, 2020, which are hereby incorporated by reference herein. Future performance and historical trends may be adversely affected by the aforementioned risks, and other variables and risks and uncertainties not currently known or that are currently expected to be immaterial may also materially and adversely affect our business, financial condition, and results of operations or the price of our common stock in the future.*

Filed Feb 5, 2021.
Source: SEC EDGAR, the filing index for accession 0001688568-21-000008. Last ingested by Listed: Oct 31, 2026, 02:14 ET. No prices; not investment advice.
